Scarica l'app Stockscreener
0.2752
7.08%
0.0182
Precedente Chiudi:
$0.257
Aprire:
$0.2668
Volume 24 ore:
6.21M
Relative Volume:
0.66
Capitalizzazione di mercato:
$49.09M
Reddito:
-
Utile/perdita netta:
$-12.89M
Rapporto P/E:
-0.1088
EPS:
-2.53
Flusso di cassa netto:
$-11.95M
1 W Prestazione:
+5.89%
1M Prestazione:
-41.46%
6M Prestazione:
-52.09%
1 anno Prestazione:
-77.07%
Intervallo 1D:
$0.26
$0.2876
Intervallo di 1 settimana:
$0.2403
$0.2876
Portata 52W:
$0.1634
$2.3099
Plus Therapeutics Inc Stock (PSTV) Company Profile
Nome
Plus Therapeutics Inc
Settore
Industria
Telefono
737.255.7194
Indirizzo
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.2752 | 45.84M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-03 | Iniziato | Lake Street | Buy |
| 2025-09-03 | Aggiornamento | D. Boral Capital | Hold → Buy |
| 2025-03-17 | Iniziato | D. Boral Capital | Buy |
| 2021-01-25 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-10-16 | Iniziato | Maxim Group | Buy |
Plus Therapeutics Inc Borsa (PSTV) Ultime notizie
Plus Therapeutics Updates Executive Compensation, Approves 2025 Bonuses - TipRanks
Aug Decliners: Can Plus Therapeutics Inc stock double in the next yearQuarterly Risk Review & Capital Efficient Trading Techniques - baoquankhu1.vn
Aug EndMonth: What is MPWRs valuation compared to sectorStock Surge & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
How Analyst Revisions Are Rewriting The Story For Plus Therapeutics (PSTV) - Yahoo Finance
Merger Talk: What is the dividend yield of Plus Therapeutics IncPortfolio Gains Summary & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Market Rankings: Is Plus Therapeutics Inc stock undervalued right nowBond Market & Daily Entry Point Alerts - baoquankhu1.vn
Exit Recap: What is Atlas Lithium Corporations revenue forecastJuly 2025 Movers & AI Enhanced Execution Alerts - baoquankhu1.vn
Is Plus Therapeutics Inc. a top pick in the sectorQuarterly Risk Review & Free Technical Pattern Based Buy Signals - mfd.ru
Bond Watch: What is the cash position of LifeMD IncJuly 2025 Momentum & Weekly High Momentum Picks - baoquankhu1.vn
Published on: 2026-01-27 09:16:26 - baoquankhu1.vn
Institution Moves: Is Plus Therapeutics Inc on track to beat earningsTrade Signal Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Price Action: Is Euroholdings Ltd. stock showing strong momentumJuly 2025 Recap & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
H.C. Wainwright lowers Plus Therapeutics stock price target on equity offering - Investing.com India
Maxim Group Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Cuts Target Price to $1.5 - 富途牛牛
Plus Therapeutics secures $5.7M to support leptomeningeal metastases program - MSN
H.C. Wainwright Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Cuts Target Price to $1 - 富途牛牛
Plus Therapeutics (PSTV) Sees Price Target Cut by HC Wainwright | PSTV Stock News - GuruFocus
Plus Therapeutics outlines 2026 goals for cancer treatments and diagnostics By Investing.com - Investing.com South Africa
Aug Mood: Is ABCL forming higher highs and higher lowsJuly 2025 Analyst Calls & Weekly Top Gainers Trade List - baoquankhu1.vn
Market Review: What dividend growth rate does Plus Therapeutics Inc offerWeekly Gains Summary & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Plus Therapeutics, Inc. Provides Business Update on REYOBIQ Clinical Program and U.S. CNSide Commercialization - marketscreener.com
PSTV: $15M raise funds clinical and commercial growth; CNSIDE targets break-even by 2027 - TradingView — Track All Markets
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET - Sahm
Plus Therapeutics Sets 2026 Milestones For REYOBIQ Clinical Program And CNSide Commercial Rollout - Nasdaq
Plus Therapeutics outlines 2026 goals for cancer treatments and diagnostics - Investing.com
PSTV Analyst Rating Update: Price Target Lowered to $4.00 | PSTV Stock News - GuruFocus
Plus Therapeutics Sharpens Focus on CNS Cancer Strategy - TipRanks
PSTV: 2026 focus: CNSide scale-up, REYOBIQ pivotal trial prep, and expanded payor coverage - TradingView
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization - manilatimes.net
Plus Therapeutics, Inc. Updates Corporate Presentation on Cancer Radiotherapeutics - TradingView
Plus Therapeutics To Provide Business Update Today As Radiotherapeutic Pipeline Advances - Nasdaq
Plus Therapeutics To Provide Business Update On Thursday - TradingView
Plus Therapeutics, Inc. to Host Business Update and Conference Call on January 22, 2026 | PSTV Stock News - Quiver Quantitative
Plus Therapeutics to Provide Business Update and Host - GlobeNewswire
Investors get Plus Therapeutics business update in Jan. 22 webcast - Stock Titan
Should you avoid Plus Therapeutics Inc stock right now2025 Winners & Losers & Verified Momentum Stock Alerts - baoquankhu1.vn
Earnings Report: Will Plus Therapeutics Inc benefit from rising consumer demand2025 Market Overview & Stock Portfolio Risk Management - baoquankhu1.vn
Growth Value: Is Plus Therapeutics Inc a cyclical or defensive stockMarket Movement Recap & AI Enhanced Execution Alerts - baoquankhu1.vn
Aug Opening: Can Plus Therapeutics Inc reach all time highs this yearLayoff News & Real-Time Volume Triggers - baoquankhu1.vn
Plus Therapeutics completes underwritten public equity offering - TipRanks
Plus Therapeutics Signs Underwriting Agreement With Lake Street Capital Markets - TradingView — Track All Markets
Plus Therapeutics Inc enters underwriting agreement with Lake Street Capital Markets, LLCSEC filing - marketscreener.com
Plus Therapeutics IncOn Jan 13, Co Enters Underwriting Agreement With Lake Street Capital Markets, LlcSEC Filing - TradingView — Track All Markets
Whale Trades: Is UONE stock suitable for long term investingJuly 2025 Earnings & Fast Moving Stock Trade Plans - baoquankhu1.vn
Analyst Downgrade: Is UDR Inc in accumulation or distribution phaseJuly 2025 Intraday Action & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering - Sahm
Plus Therapeutics prices $15 million public offering at $0.38 per unit - Investing.com Nigeria
Plus Therapeutics Prices Public Offering, Raising $15 Million - Intellectia AI
Plus Therapeutics Spurs After-Hours Biotech Rally; Connect Biopharma And Elutia Also Advance - Nasdaq
Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - MSN
Plus Therapeutics Inc Azioni (PSTV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):